Coagulation and inflammation in acute lung injury

Thrombosis and Haemostasis

Volumn 88, Issue 1, 2002, Pages 17-25

  Welty Wolf, Karen E ^a   Carraway, Martha S ^a   Ortel, Thomas L ^a   Piantadosi, Claude A ^a  

^a DUKE UNIVERSITY   (United States)

Author keywords

Acute respiratory distress syndrome; Sepsis; Thromboplastin

Indexed keywords

BLOOD CLOTTING FACTOR 10A; BLOOD CLOTTING FACTOR 7A; CYTOKINE; ENDOTOXIN; FIBRIN; INTERLEUKIN 6; LUNG SURFACTANT; PLASMINOGEN ACTIVATOR; PROCOAGULANT; PROTEIN C; RECOMBINANT ANTITHROMBIN III; THROMBIN; THROMBIN INHIBITOR; THROMBOPLASTIN; TISSUE FACTOR PATHWAY INHIBITOR; ANTICOAGULANT AGENT; BLOOD CLOTTING FACTOR;

ACUTE DISEASE; BACTERIAL GROWTH; BLOOD CLOTTING; CELL ACTIVATION; CELL MIGRATION; CLINICAL TRIAL; DISEASE SEVERITY; DRUG TARGETING; FIBRIN DEPOSITION; HUMAN; INFLAMMATORY CELL; LUNG ALVEOLUS; LUNG ALVEOLUS MACROPHAGE; LUNG BLOOD VESSEL; LUNG EXTRAVASCULAR FLUID; LUNG INJURY; LUNG LAVAGE; LUNG PARENCHYMA; PATHOGENESIS; PNEUMONIA; PRIORITY JOURNAL; RESPIRATORY DISTRESS SYNDROME; REVIEW; SEPSIS; ADULT RESPIRATORY DISTRESS SYNDROME; ANIMAL; BLOOD; BLOOD CLOTTING DISORDER; INFLAMMATION; METABOLISM; PATHOLOGY;

ANIMALS; ANTICOAGULANTS; BLOOD COAGULATION DISORDERS; BLOOD COAGULATION FACTORS; HUMANS; INFLAMMATION; RESPIRATORY DISTRESS SYNDROME, ADULT;

EID: 0036305113     PISSN: 03406245     EISSN: None     Source Type: Journal    
DOI: 10.1055/s-0037-1613147     Document Type: Review

References (109)

1. Acute respiratory distress in adults
2. Structural alterations of lung parenchyma in the adult respiratory distress syndrome
3. Extravascular coagulation and fibrin deposition in acute lung injury
4. Incidence and outcome of the respiratory distress syndrome in gram-negative sepsis
5. The risk factors, incidence, and prognosis of ARDS following septicemia
6. Gram-negative bacteremia. IV. Re-evaluation of clinical features and treatment in 612 patients
7. The acute respiratory distress syndrome
8. Neutrophil-mediated tissue injury and its modulation
9. Inflammatory cytokines in patients with persistence of the acute respiratory distress syndrome
10. Why immunomodulatory therapies have not worked in sepsis
11. Thirty years of clinical trials in acute respiratory distress syndrome
12. Experimental endotoxemia in humans: Analysis of cytokine release and coagulation, fibrinolytic, and complement pathways
13. Complete inhibition of endotoxin-induced coagulation activation in chimpanzees with a monoclonal Fab fragment against factor VII/VIIa
14. Inhibition of endotoxin-induced activation of coagulation and fibrinolysis by pentoxyphylline or by a monoclonal anti-tissue factor antibody in chimpanzees
15. The in vivo kinetics of tissue factor messenger RNA expression during human endotoxemia: Relationship with activation of coagulation
16. Elimination of IL-6 attenuates coagulation activation in experimental endotoxemia in chimpanzees
17. Differential effects of anti-tumor necrosis factor monoclonal antibodies on systemic inflammatory responses in experimental endotoxemia in chimpanzees
18. The cytokine-mediated imbalance between coagulant and anticoagulant mechanisms in sepsis and endotoxaemia
19. Inflammatory cytokines in the BAL of patients with ARDS. Persistent elevation over time predicts poor outcome
20. Contribution of interleukin-1 to activation of coagulation and fibrinolysis, neutrophil degranulation, and the release of secretory-type phospholipase A2 in sepsis: Studies in non-human primates after interleukin-1 alpha administration and during lethal bacteremia
21. Fibrinolytic response to tumor necrosis factor in healthy subjects
22. Survival of primates in LD100 septic shock following therapy with antibody to tumor necrosis factor (TNF)
23. Septic shock, multiple organ failure and disseminated intravascular coagulation: Compared patterns of antithrombin III, protein C and protein S deficiencies
24. Heparin promotes the inactivation of antithrombin by neutrophil elastase
25. The protein C pathway
26. Protein C prevents the coagulopathic and lethal effects of Escherichia coli infusion in the baboon
27. Antithrombin-III prevents the lethal effects of Escherichia coli infusion in baboons
28. Tissue factor pathway inhibitor: Potential therapeutic applications
29. Heterogeneity in the incidence and clinical manifestations of disseminated intravascular coagulation: A study of 204 cases
30. Expression of tissue factor and tissue factor pathway inhibitor in rat lungs with lipopolysaccharide-induced disseminated intravascular coagulation
31. Combined antithrombin III and C1-esterase inhibitor treatment decreases intravascular fibrin deposition and attenuates cardiorespiratory impairment in rabbits exposed to Escherichia coli endotoxin
32. Recombinant human protein C Worldwide Evaluation in Severe Sepsis (PROWESS) study group. Efficacy and safety of recombinant human activated protein C for severe sepsis
33. Coagulation inhibitor replacement during sepsis: Useless?
34. Differential effects of anti-cytokine treatment on bronchoalveolar hemostasis in endotoxemic chimpanzees
35. Local abnormalities of coagulation and fibrinolytic pathways that promote alveolar fibrin deposition in the lungs of baboons with diffuse alveolar damage
36. Serial abnormalities of fibrin turnover in evolving adult respiratory distress syndrome
37. Local abnormalities in coagulation and fibrinolytic pathways predispose to alveolar fibrin deposition in the adult respiratory distress syndrome
38. Selective cellular expression of tissue factor in human tissues. Implications for disorders of hemostasis and thrombosis
39. Tissue factor in bronchoalveolar lavage fluids. Evidence for an alveolar macrophage source
40. Glomerular tissue factor expression in crescentic glomerulonephritis. Correlations between antigen, activity, and mRNA
41. Regulation of the tissue factor gene in human monocytic cells. Role of AP-1, NF-kappa B/Rel, and Sp1 proteins in uninduced and lipopolysaccharide-induced expression
42. Biology of acute lung injury
43. Inflammatory cell participation in coagulation
44. Plasminogen activators, integrins, and the coordinated regulation of cell adhesion and migration
45. Wound-healing defects in mice lacking fibrinogen
46. Fibrinogen activates NF-kappa B transcription factors in mononuclear phagocytes
47. Transcriptional regulation of the interleukin-1beta promoter via fibrinogen engagement of the CD18 integrin receptor
48. Alteration of surfactant function due to protein leakage: Special interaction with fibrin monomer
49. Proteolytic cleavage of fibrinogen: Amplification of its surfactant inhibitory capacity
50. The effect of surface-active lipoprotein on clotting, fibrinolysis, and of fibrinogen on the surface tension of surface-active lipoprotein
51. Plasminogen activator inhibitor-1 in acute hyperoxic mouse lung injury
52. Bleomycin-induced pulmonary fibrosis in transgenic mice that either lack or overexpress the murine plasminogen activator inhibitor-1 gene
53. Coagulation blockade prevents sepsis-induced respiratory and renal failure in baboons
54. Abnormalities of pathways of fibrin turnover in lung lavage of rats with oleic acid and bleomycin-induced lung injury support alveolar fibrin deposition
55. Tissue fibrin deposition during acute lung injury in rabbits and its relationship to local expression of procoagulant and fibrinolytic activities
56. The yin and yang of fibrin in the airways
57. Bleomycin-induced pulmonary fibrosis in fibrinogen-null mice
58. Structural design and molecular evolution of a cytokine receptor superfamily
59. Binding of human factor VIIa to tissue factor induces cytosolic Ca2+ signals in J82 cells, transfected COS-1 cells, Madin-Darby canine kidney cells and in human endothelial cells induced to synthesize tissue factor
60. Coagulation factors VII and X induce Ca2+ oscillations in Madin-Darby canine kidney cells only when proteolytically active
61. Tissue factor-dependent factor VIIa signaling
62. A role for tissue factor in cell adhesion and migration mediated by interaction with actin-binding protein 280
63. Binding of factor VIIa to tissue factor on keratinocytes induces gene expression
64. Factor VIIa-induced p44/42 mitogen-activated protein kinase activation requires the proteolytic activity of factor VIIa and is independent of the tissue factor cytoplasmic domain
65. Signal transduction via the mitogen-activated protein kinase pathway induced by binding of coagulation factor FVIIa to tissue factor
66. Effect of human recombinant interleukin-6 and interleukin-8 on monocyte procoagulant activity
67. Binding of factor VIIa to tissue factor induces alterations in gene expression in human fibroblast cells: Upregulation of poly(A) polymerase
68. Do the poly(A) tail and 3′ untranslated region control mRNA translation?
69. Tissue factor- and factor X-dependent activation of protease-activated receptor 2 by factor VIIa
70. Tissue factor and factor VIIa receptor/ligand interactions induce proinflammatory effects in macrophages
71. Enhanced expression of urokinase receptor induced through the tissue factor-factor VIIa pathway in human pancreatic cancer
72. Urokinase receptor-deficient mice have impaired neutrophil recruitment in response to pulmonary Pseudomonas aeruginosa infection
73. Tissue factor-dependent vascular endothelial growth factor production by human fibroblasts in response to activated factor VII
74. Regulation of vascular endothelial growth factor production and angiogenesis by the cytoplasmic tail of tissue factor
75. Vascular endothelial growth factor, a potent and selective angiogenic agent
76. The biology of vascular endothelial growth factor
77. Lung over-expression of the vascular endothelial growth factor gene induces pulmonary edema
78. Endothelin 1 and thrombin synergistically stimulate IL-6 mRNA expression and protein production in human umbilical vein endothelial cells
79. Protease-activated receptors and their role in IL-6 and NF-IL-6 expression in human gingival fibroblasts
80. Thrombin receptor mediated signals induce expressions of interleukin 6 and granulocyte colony stimulating factor via NF-kappa B activation in synovial fibroblasts
81. Gene induction by coagulation factor Xa is mediated by activation of protease-activated receptor 1
82. Factor Xa as an interface between coagulation and inflammation. Molecular mimicry of factor Xa association with effector cell protease receptor-1 induces acute inflammation in vivo
83. Effector cell protease receptor 1 is a vascular receptor for coagulation factor Xa
84. Effector protease receptor 1 mediates the mitogenic activity of factor Xa for vascular smooth muscle cells in vitro and in vivo
85. Introduction: Are natural anticoagulants candidates for modulating the inflammatory response to endotoxin?
86. Coagulation factors VIIa and Xa induce cell signaling leading to up-regulation of the egr-1 gene
87. In vivo immunosuppression by targeting a novel protease receptor
88. Thrombin signaling and protease-activated receptors
89. Inflammatory roles of P-Selectin
90. Recombinant human activated protein C: A system modulator of vascular function for treatment of severe sepsis
91. Gene expression profile of antithrombotic protein c defines new mechanisms modulating inflammation and apoptosis
92. Human protein C receptor is present primarily on endothelium of large blood vessels: Implications for the control of the protein C pathway
93. Tissue factor pathway inhibitor with high anticoagulant activity is expressed in post-heparin plasma and in plasma from cancer patients
94. Tissue factor pathway inhibitor and von Willebrand factor antigen levels in adult respiratory distress syndrome and in a primate model of sepsis
95. Recombinant tissue factor pathway inhibitor reduced lipopolysaccharide-induced pulmonary vascular injury by inhibiting leukocyte activation
96. The activity of tissue factor pathway inhibitor in experimental models of superantigen-induced shock and polymicrobial intra-abdominal sepsis
97. Prostacyclin and beraprost sodium as suppressors of activated rat polymorphonuclear leukocytes
98. Therapeutic use of antithrombin concentrate in sepsis
99. Stimulation of pulmonary big endothelin-1 and endothelin-1 by antithrombin III: A rationale for combined application of antithrombin III and endothelin antagonists in sepsis-related acute respiratory distress syndrome?
100. Lethal E. coli septic shock is prevented by blocking tissue factor with monoclonal antibody
101. Tissue factor pathway inhibitor reduces mortality from Eschericia coli septic shock
102. Active site inhibited Factor VIIa (DEGR VIIa) attenuates the coagulant and interleukin-6 and -8, but not tumor necrosis factor, responses of the baboon to LD100 Eschericia coli
103. Recombinant human antithrombin III improves survival and attenuates inflammatory responses in baboons lethally challenged with Eschericia coli
104. DEGR-Factor Xa blocks disseminated intravascular coagulation initiated by Escherichia coli without preventing shock or organ damage
105. Tissue factor pathway inhibitor dose-dependently inhibits coagulation activation without influencing the fibrinolytic and cytokine response during human endotoxemia
106. High-dose antithrombin III in severe sepsis: A randomized controlled trial
107. Alpha-thrombin-induced pulmonary vasoconstriction
108. Effect of recombinant hirudin, a specific inhibitor of thrombin, on endotoxin-induced intravascular coagulation and acute lung injury in pigs
109. Tissue factor inhibition and clinical trial results of tissue factor pathway inhibition in sepsis